Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Related TEVA
Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Revenue
Teva Reports Results of Strategic Review, Sees 14 Pipeline Projects Possible for Divestment, Discontinuation
Sofinnova Ventures Closes $500M Fund (Fox Business)
Related NVS
Drug ETFs Attractive Buys On Pullback
US Stock Futures Signal Lower Start On Wall Street
Bayer Buys Merck Consumer Care Unit (Fox Business)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA


Related Articles (TEVA + NVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters